Loading…
← CockpitCompetitor Analysis › SRRK Scholar Rock Holding Corp.Open in the cockpit ↗

Scholar Rock Holding Corp.SRRKCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.

Momentum neutral 56
Mkt cap
$5.86B
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$72.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$48.00
1D+6.5%
1W+3.0%
1M+16.1%
3M-13.1%
6M-0.8%
YTD+9.0%
1Y+31.6%
ATR %5.3%
Beta1.01
52w lowhigh22.3% off high

What Scholar Rock does

Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.

Has no approved product yet, so it is funded by money raised from investors rather than sales. Any future income would come from selling apitegromab as an add-on to existing spinal muscular atrophy treatments, which work on the nerve cells while apitegromab targets muscle.

Products and services

  • Apitegromab (spinal muscular atrophy, pipeline)
  • Pipeline: obesity-related muscle preservation

Customers

  • Neurologists treating spinal muscular atrophy (pen

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Muscle/growth-factor targeted drug…

What could go right

  • Apitegromab approval as an add-on to SMA gene therapies
  • Muscle-preservation opportunity alongside GLP-1 obesity drugs

What could go wrong

  • Pre-revenue, binary late-stage trial risk
  • Small SMA patient population

Moat: narrow (IP / patents). A selective myostatin-pathway inhibitor differentiated by targeting muscle growth alongside SMA gene therapies.

Headquarters: Cambridge, Massachusetts, US · Founded: 2012 · Employees: 289

Named competitors

Scholar Rock at a glance

Size Scholar Rock (SRRK) is a United States Health Care company (Biotechnology) with a market value of $5.86B, the 1068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.00 on 18 Nov 2026.

Performance Over six months the shares fell 0.8%, against -3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth The operating margin is -71,732.3% (peer median -15.6%).

Valuation It trades at 9,900.4× enterprise value to sales against a peer median of 11.3× (most expensive of 16).

Short interest Short interest is 19.3% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026SRRK 101Peer median 98
Six months, rebased to 100: Scholar Rock against the median of its 20 peers (local-currency closes).

Scholar Rock financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$570,000$0$0$0$33.2M
Revenue growth———-100%—
Gross profit-$753,000-$1.66M-$1.94M-$2.84M$23.3M
EBITDA-$408M-$383M-$250M-$168M-$124M
Net income-$414M-$378M-$246M-$166M-$135M
Free cash flow-$310M-$301M-$201M-$145M-$134M
Capital expenditure$202,000$602,000$98,000$71,000$1.06M
Total debt$203M$109M$65.1M$61.8M$69.4M

Quarterly statements and history in the cockpit →

Scholar Rock competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%ARWRCAIANTHEMKOD300122IMVT300347AXSMCOGTCGONDNTHADPT002252TXGEWTX000661TWST1530603392SMMTSRRK6-month return →1-month return →
Up and to the right = strong over both horizons. Scholar Rock is the large dot.

Scholar Rock competitors and peer comparison

Head to head with its named competitors (SRRK vs NOVN.SW vs RO.SW vs BIIB)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Scholar Rock SRRK$5.86B-1%n/a-71,732%9,900.4×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Roche RO.SW$381B+21%-1%31%5.7×1.7%
Biogen BIIB$37.2B+34%+2%17%4.4×10.1%
Biohaven BHVN$1.95B+46%n/an/an/an/a
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%

How Scholar Rock compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Scholar Rock against its 20 peers (data as of 18 Nov 2026)
MeasureSRRKPeer medianRank in peer set
1-month return+16.1%-7.1%4th highest of 21
6-month return-0.8%-3.5%9th highest of 21
Distance from 52-week high-22.3%-33.1%6th highest of 21
Operating margin-71,732.3%-15.6%lowest of 16
EV / Sales9,900.4×11.3×most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%8.0×n/an/a
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%1,000.7×n/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%11.3×47.2%+16.6%
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Twist Bioscience TWSTUnited States$7.93B+117%+22%-29%16.2×n/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Summit Therapeutics SMMTUnited States$8.40B-41%n/an/an/an/an/a

Questions

Who are Scholar Rock's main competitors?
Named competitors: Novartis (Zolgensma) (NOVN.SW), Roche (Evrysdi) (RO.SW), Biogen (Spinraza) (BIIB), Biohaven (BHVN), Regeneron (REGN), Eli Lilly (LLY). The cockpit's measured peer set (industry) also includes Arrowhead Pharmaceuticals (ARWR), Caris Life Sciences (CAI), Anthem Biosciences (ANTHEM.NS), Kodiak Sciences (KOD), Chongqing Zhifei Biological Products (300122.SZ), Immunovant (IMVT).
Is Scholar Rock expensive compared with its peers?
On ev / sales it trades at 9,900.4× against a peer median of 11.3×, most expensive of 16 in its peer set.
How has Scholar Rock stock performed?
Over six months to 18 Nov 2026 the shares returned -0.8% against -3.5% for the median peer; over one year +31.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.